Eruptive melanocytic nevi associated with ponatinib
| Autor: | Catherine Lok, Inès Devred, Stéphanie Trudel, Guillaume Chaby, Delphine Rea, Florian Lombart, Henri Sevestre, Jean-Philippe Arnault, Alanoud Adas |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
medicine.drug_class EMN eruptive melanocytic nevi Case Report Dermatology TKI tyrosine kinase inhibitor drugs Tyrosine-kinase inhibitor Food and drug administration 030207 dermatology & venereal diseases 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine CML chronic myeloid leukemia chronic myeloid leukemia hemic and lymphatic diseases Dry skin medicine ponatinib Adverse effect Eruptive melanocytic nevi eruptive melanocytic nevi business.industry Ponatinib Myeloid leukemia ALL acute lymphoblastic leukemia Rash chemistry 030220 oncology & carcinogenesis adverse effects Ph+ Philadelphia chromosome–positive medicine.symptom business |
| Zdroj: | JAAD Case Reports |
| ISSN: | 2352-5126 |
| DOI: | 10.1016/j.jdcr.2018.07.010 |
| Popis: | Ponatinib (ICLUSIG, Takeda; Osaka, Japan) is an oral third-generation tyrosine kinase inhibitor (TKI) approved by US Food and Drug Administration in 2012 used to treat chronic myeloid leukemia (CML) and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL), for whom no other tyrosine kinase inhibitor therapy is indicated, and for patients with T3151+ CML or T315I Ph+ ALL.1 Skin rash and dry skin are the most frequent dermatologic adverse effects, reported as high as 34% and 32%, respectively.1 Recently, pityriasiform and ichthyosiform cutaneous toxicities were also reported, sometimes associated with eyebrow alopecia.2 Here, we report the first case, to our knowledge, of eruptive melanocytic nevi (EMN) induced by ponatinib, an adverse effect previously reported with a few other TKI. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|